Amgen's most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $180.00 short put and a strike $170.00 long put offers a potential 15.07% return on risk over the next 31 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $180.00 by expiration. The full premium credit of $1.31 would be kept by the premium seller. The risk of $8.69 would be incurred if the stock dropped below the $170.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Amgen is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.
The RSI indicator is at 65.48 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Why this Peninsula cell therapy company joined biotech's 'unprecedented' manufacturing boom
Mon, 18 Jun 2018 13:42:34 +0000
Advances in cell and gene therapy are setting off a biotech manufacturing building boom. This South San Francisco-based company is one of the latest to open a new facility.
Amgen Inc (NASDAQ:AMGN): Time For A Financial Health Check
Fri, 15 Jun 2018 00:21:20 +0000
The size of Amgen Inc (NASDAQ:AMGN), a US$122.46B large-cap, often attracts investors seeking a reliable investment in the stock market. Doing business globally, large caps tend to have diversified revenueRead More…
Allergan (AGN) Presents Positive Data on Glaucoma Candidate
Thu, 14 Jun 2018 15:31:03 +0000
Allergan (AGN) posts positive top-line data from a phase III study on Bimatoprost SR, a biodegradable implant for reducing IOP in patients with open-angle glaucoma or ocular hypertension.
Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod
Wed, 13 Jun 2018 14:34:02 +0000
Key areas of focus in the biotech space include regulatory approvals and licensing/acquisition deals.
Initiating Free Research Reports on ArQule and Three Other Biotech Equities
Wed, 13 Jun 2018 11:25:00 +0000
In today's pre-market research, four stocks are presented for scanning: AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), Amgen Inc. (NASDAQ: AMGN), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and ArQule Inc. (NASDAQ: ARQL). Shares in Waltham, Massachusetts headquartered AMAG Pharmaceuticals Inc. saw a slight decline of 0.62%, ending Tuesday's trading session at $23.95.
Also on Market Tamer…
Follow Us on Facebook